In their landmark prospective study, Hofman et al. selected patients for tumor sites showing an SUVmax at least 1.5 times the normal liver uptake, whilst excluding FDG-positive disease with low PSMA expression by dual FDG and PSMA-PET/CT baseline imaging [7]. This evidence concerns the gene FOLH1 and neoplasm.